Tesamorelin + Ipamorelin

Overview

Pre-mixed blend of Tesamorelin (a stabilized GHRH(1-44) analog) and Ipamorelin (a selective ghrelin-receptor agonist). Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy; Ipamorelin is not FDA-approved. The blend itself is NOT clinically validated — no controlled trial has tested Tesamorelin co-administered with Ipamorelin. Evidence is inferred from the individual components.

Mechanism of Action

Tesamorelin binds the pituitary GHRH receptor (Falutz et al., NEJM 2007, demonstrated GH/IGF-1 elevation and visceral fat reduction as monotherapy). Ipamorelin selectively activates GHS-R1a without meaningful cortisol/prolactin elevation (Raun et al., 1998). The broader pharmacological principle of GHRH + GHRP synergy for pulsatile GH amplification is established with other pairs (Veldhuis & Bowers, 2009), but has not been demonstrated for this specific combination.

Research Summary

Tesamorelin has Phase 3 monotherapy data in HIV-associated visceral adiposity. There is no published human trial of Tesamorelin + Ipamorelin co-administration. The blend is a vendor formulation, not a clinically validated protocol.

Vendors selling Tesamorelin + Ipamorelin

Scored vendors carrying Tesamorelin + Ipamorelin, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Prescribers who offer Tesamorelin + Ipamorelin

5 prescribers in our directory work with Tesamorelin + Ipamorelin, each confirmed from their own website. Peptides like Tesamorelin + Ipamorelin require a prescription from a licensed provider — telehealth options are available.

Reported Side Effects

• See individual compound profiles for Tesamorelin and Ipamorelin

Research References

• Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. (2007)
• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. (1998)
• Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092. (2009)

Frequently asked questions

Has Tesamorelin + Ipamorelin been independently lab-tested?

Disclosed Labs has collected 37 Certificates of Analysis (COA) for Tesamorelin + Ipamorelin from 9 independent testing labs. 18 vendors have submitted material for testing. Products average 99.5% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/tesamorelin-ipamorelin/testing.

What is the average purity of Tesamorelin + Ipamorelin on the market?

Based on 37 COAs analyzed by Disclosed Labs, Tesamorelin + Ipamorelin products average 99.5% (±0.8%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/tesamorelin-ipamorelin/coas.

Which labs have tested Tesamorelin + Ipamorelin?

Independent labs that have tested Tesamorelin + Ipamorelin include: ILS Labs (Grade A), Ethos Analytics (Grade B). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

Where can researchers source Tesamorelin + Ipamorelin?

8 vendors with Disclosed Labs trust grades currently list Tesamorelin + Ipamorelin, including Instant Peptides, Glacier Aminos, Ion Peptide. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/tesamorelin-ipamorelin.

Which prescribers offer Tesamorelin + Ipamorelin with a prescription?

5 prescribers in the Disclosed Labs directory work with Tesamorelin + Ipamorelin, each confirmed from their own website, with telehealth options available. Tesamorelin + Ipamorelin requires a prescription from a licensed provider. Browse them at https://www.disclosedlabs.com/prescribers?peptide=Tesamorelin%20%2B%20Ipamorelin.

How does Tesamorelin + Ipamorelin work?

Tesamorelin binds the pituitary GHRH receptor (Falutz et al., NEJM 2007, demonstrated GH/IGF-1 elevation and visceral fat reduction as monotherapy). Ipamorelin selectively activates GHS-R1a without meaningful cortisol/prolactin elevation (Raun et al., 1998). The broader pharmacological principle of GHRH + GHRP synergy for pulsatile GH amplification is established with other pairs (Veldhuis & Bowers, 2009), but has not been demonstrated for this specific combination.

What does the research say about Tesamorelin + Ipamorelin?

Tesamorelin has Phase 3 monotherapy data in HIV-associated visceral adiposity. There is no published human trial of Tesamorelin + Ipamorelin co-administration. The blend is a vendor formulation, not a clinically validated protocol.